Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Bioresour Technol ; 337: 125490, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34320769

RESUMEN

In the present study, starch-based potato peel waste biomass (PWB) was utilized as a potential substrate for hydrogen production via dark fermentation by the thermophillic amylase producing strain Parageobacillus thermoglucosidasius KCTC 33548. Supplementation of Fe3O4 nanoparticles (300 mg/L) led to a 4.15-fold increase in hydrogen production as compared to the control. The addition of optimized concentrations of both Fe3O4 nanoparticles (300 mg/L) and L-cysteine (250 mg/L) during hydrogen fermentation using pure starch and PWB generated maximum cumulative hydrogen yields of 167 and 71.9 mL with maximum production rates of 2.81 and 1.26 mL/h, respectively. Further, the correlation between Fe3O4 and the expression of hydrogenase isoforms and the related hydrogenase activity was explored. The possible mechanisms of the action of Fe3O4 on enhanced hydrogenase activity and hydrogen production was elucidated. To our knowledge, there are no such studies reported on enhanced hydrogen production from PWB in a single step.


Asunto(s)
Nanopartículas , Solanum tuberosum , Bacillaceae , Biomasa , Fermentación , Hidrógeno , Almidón/metabolismo
2.
Arterioscler Thromb Vasc Biol ; 41(1): 390-400, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33176447

RESUMEN

OBJECTIVE: The platelet phenotype in certain patients and clinical contexts may differ from healthy conditions. We evaluated platelet activation through specific receptors in healthy men and women, comparing this to patients presenting with ST-segment-elevation myocardial infarction and non-ST-segment-elevation myocardial infarction. Approach and Results: We identified independent predictors of platelet activation through certain receptors and a murine MI model further explored these findings. Platelets from healthy women and female mice are more reactive through PARs (protease-activated receptors) compared with platelets from men and male mice. Multivariate regression analyses revealed male sex and non-ST-segment-elevation myocardial infarction as independent predictors of enhanced PAR1 activation in human platelets. Platelet PAR1 signaling decreased in women and increased in men during MI which was the opposite of what was observed during healthy conditions. Similarly, in mice, thrombin-mediated platelet activation was greater in healthy females compared with males, and lesser in females compared with males at the time of MI. CONCLUSIONS: Sex-specific signaling in platelets seems to be a cross-species phenomenon. The divergent platelet phenotype in males and females at the time of MI suggests a sex-specific antiplatelet drug regimen should be prospectively evaluated.


Asunto(s)
Plaquetas/metabolismo , Infarto del Miocardio sin Elevación del ST/sangre , Activación Plaquetaria , Receptor PAR-1/sangre , Infarto del Miocardio con Elevación del ST/sangre , Anciano , Animales , Plaquetas/efectos de los fármacos , Estudios de Casos y Controles , Modelos Animales de Enfermedad , Femenino , Humanos , Masculino , Ratones Endogámicos C57BL , Persona de Mediana Edad , Fenotipo , Activación Plaquetaria/efectos de los fármacos , Factores Sexuales , Transducción de Señal , Trombina/farmacología
3.
Circ Arrhythm Electrophysiol ; 13(6): e008662, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32347743

RESUMEN

BACKGROUND: The novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus disease 2019 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine±azithromycin for the treatment of coronavirus disease 2019. Use of these medications alone, or in combination, can lead to a prolongation of the QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death. METHODS: Hospitalized patients treated with chloroquine/hydroxychloroquine±azithromycin from March 1 to the 23 at 3 hospitals within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval were performed. The primary outcome was QT prolongation resulting in Torsade de pointes. Secondary outcomes included QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongation, and arrhythmogenic death. RESULTS: Two hundred one patients were treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine. Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithromycin. The primary outcome of torsade de pointes was not observed in the entire population. Baseline corrected QT interval intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6±24.9 versus 439.9±24.7 ms, P=0.834). The maximum corrected QT interval during treatment was significantly longer in the combination group versus the monotherapy group (470.4±45.0 ms versus 453.3±37.0 ms, P=0.004). Seven patients (3.5%) required discontinuation of these medications due to corrected QT interval prolongation. No arrhythmogenic deaths were reported. CONCLUSIONS: In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported. Although use of these medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT interval monitoring is needed before final recommendations can be made.


Asunto(s)
Arritmias Cardíacas/inducido químicamente , Azitromicina/efectos adversos , Betacoronavirus , Cloroquina/efectos adversos , Infecciones por Coronavirus/tratamiento farmacológico , Electrocardiografía/efectos de los fármacos , Hidroxicloroquina/efectos adversos , Neumonía Viral/tratamiento farmacológico , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Antimaláricos/efectos adversos , Antimaláricos/uso terapéutico , Arritmias Cardíacas/complicaciones , Arritmias Cardíacas/epidemiología , Azitromicina/uso terapéutico , COVID-19 , Cloroquina/uso terapéutico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/fisiopatología , Quimioterapia Combinada , Estudios de Seguimiento , Humanos , Hidroxicloroquina/uso terapéutico , Incidencia , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/fisiopatología , Estudios Prospectivos , Factores de Riesgo , SARS-CoV-2 , Estados Unidos/epidemiología
4.
J Cardiovasc Electrophysiol ; 31(4): 860-867, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32048776

RESUMEN

INTRODUCTION: The need for transvenous lead extractions due to cardiac implantable electronic device (CIED)-related infections continues to rise. Current guidelines recommend complete device removal in the setting of an active infection, which can be challenging in pacemaker-dependent patients. METHODS: We retrospectively reviewed all leadless pacemaker implants between January 2018 and November 2019 and identified a subset of patients who had undergone a concomitant CIED extraction in the setting of an active infection. Baseline characteristics, procedural details, and clinical follow-ups were recorded. RESULTS: Seventeen patients received a leadless pacemaker during the same procedure as the CIED extraction. There were no procedural complications. All patients were being treated for an active CIED infection at the time of the procedure. Fourteen patients (82.4%) were completely pacemaker-dependent and four patients (23.5%) had positive blood cultures at the time of the leadless pacemaker implantation. During a median follow-up of 143 days (interquartile range: 57, 181 days), there were no recurrent infections. CONCLUSION: Simultaneous leadless pacemaker implantation and CIED extraction are safe and feasible in the setting of an active infection. This strategy may be particularly useful in patients that are pacemaker-dependent.


Asunto(s)
Arritmias Cardíacas/terapia , Remoción de Dispositivos , Marcapaso Artificial/efectos adversos , Implantación de Prótesis/instrumentación , Infecciones Relacionadas con Prótesis/cirugía , Anciano , Anciano de 80 o más Años , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/fisiopatología , Remoción de Dispositivos/efectos adversos , Femenino , Humanos , Masculino , Implantación de Prótesis/efectos adversos , Infecciones Relacionadas con Prótesis/diagnóstico , Infecciones Relacionadas con Prótesis/microbiología , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA